Syndax Pharmaceuticals, Inc

(NASDAQ:SNDX)

Latest On Syndax Pharmaceuticals, Inc (SNDX):

Date/Time Type Description Signal Details
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01N/A
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 02:38 ESTNewsSyndax Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-04 02:40 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:35 ESTNewsSyndax Pharmaceuticals: 2023 Is A Pivotal YearN/A
2023-03-01 01:25 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04N/A
2023-02-27 19:50 ESTNewsSyndax Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-12 14:22 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowN/A
2022-12-17 03:56 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & ExpositionN/A
2022-12-12 19:48 ESTNewsKura Oncology falls, Syndax gains after Phase 1/2 data for leukemia candidatesN/A
2022-12-10 16:27 ESTNewsSyndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain ProspectN/A
2022-12-07 20:58 ESTNewsSyndax Pharmaceuticals prices $150M offeringN/A
2022-12-07 01:27 ESTNewsSyndax Pharma to sell $150M stock in public offeringN/A
2022-12-05 14:27 ESTNewsSyndax receives breakthrough therapy tag for revumenib to treat acute leukemiaN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 08:33 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidanceN/A
2022-11-02 23:19 ESTNewsSyndax Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62N/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 07:37 ESTNewsSyndax Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-13 12:56 ESTNewsKeith Goldan joins Syndax Pharmaceuticals as CFON/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 16:51 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.63N/A
2022-05-09 00:26 ESTNewsSyndax Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 05:11 ESTNewsSyndax Pharmaceuticals: Cash-Rich With 2 Promising DrugsN/A
2022-03-25 00:25 ESTNewsSyndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare ConferenceN/A
2022-03-02 06:49 ESTNewsSyndax appoints former Alnylam executive as new medical chiefN/A
2022-03-02 06:49 ESTNewsSyndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92MN/A
2022-03-02 06:48 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 18:56 ESTNewsSyndax Pharmaceuticals Q4 Earnings PreviewN/A
2022-01-29 06:36 ESTNewsSyndax Pharmaceuticals (SNDX) Investor Presentation - SlideshowN/A
2021-12-23 00:22 ESTNewsSyndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemiaN/A
2021-12-16 14:02 ESTNewsSyndax Pharma raises $75M via stock offeringN/A
2021-12-15 18:28 ESTNewsSyndax Pharmaceuticals drops 6% following underwritten stock offeringN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals EPS misses by $0.35, misses on revenueN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-14 18:13 ESTNewsSyndax Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-04 16:35 ESTNewsSyndax Pharma falls after updating early-stage data for leukemia therapyN/A
2021-10-05 15:59 ESTNewsSyndax Pharma CFO Daphne Karydas to resign to pursue another opportunityN/A
2021-09-28 02:06 ESTNewsIncyte and Syndax in pact for xatilimab targeting immune-related conditionsN/A
2021-08-10 12:01 ESTNewsSyndax Pharmaceuticals EPS beats by $0.28, beats on revenueN/A
2021-08-10 12:00 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 11:59 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:04 ESTNewsSyndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 DataN/A
2021-07-22 02:02 ESTNewsCanopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst actionN/A
2021-07-22 01:35 ESTNewsSyndax shares rise on FDA Fast Track status for leukemia treatment SNDX-5613N/A

About Syndax Pharmaceuticals, Inc (SNDX):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Syndax Pharmaceuticals, Inc
  • Symbol SNDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2016-03-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syndax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 634.74
  • Price/Book (Most Recent Quarter) 4.43
  • Enterprise Value Revenue 542.55
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.19
  • Next Year EPS Estimate -$2.17
  • Next Quarter EPS Estimate -$0.47
  • Operating Margin -4708%
  • Return on Assets -25%
  • Return on Equity -52%
  • Revenue 1.52 million
  • Earnings Per Share -$2.36
  • Revenue Per Share $0.04
  • Gross Profit 1.52 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.16 billion
  • EBITDA -67280000
  • PE Ratio -126.36
  • Analyst Target Price $32.14
  • Book Value Per Share $5.27
View More

Share Statistics

  • Shares Outstanding 48.24 million
  • Shares Float 42.95 million
  • % Held by Insiders 645%
  • % Held by Institutions 78.88%
  • Shares Short 4.93 million
  • Shares Short Prior Month 4.93 million
  • Short Ratio 9.27
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.84
  • 52 Week High $27.12
  • 52 Week Low $8.18
  • 50 Day Moving Average 22.33
  • 200 Day Moving Average 20.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syndax Pharmaceuticals, Inc (SNDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syndax Pharmaceuticals, Inc (SNDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-08$380000-$0.44-$0.5113.23%
2020-09-302020-11-02$N/A-$0.46-$0.43-6.75%
2020-06-302020-08-06$N/A-$0.42-$0.444.76%
2020-03-312020-05-07$379000-$0.56-$0.53-6.65%
2019-12-312020-03-03$380000-$0.44-$0.43-1.31%
2019-09-302019-11-07$379000-$0.41-$0.4813.92%
2019-06-302019-08-07$379000-$0.47-$0.470.76%
2019-03-312019-05-06$379000-$0.53-$0.554.14%
2018-12-312019-03-07$379000-$0.70-$0.64-9.43%
2018-09-302018-11-05$379000-$0.68-$0.7610.21%
2018-06-302018-08-07$379000-$0.74-$0.8916.94%
2018-03-312018-05-08$379000-$0.79-$0.9517.15%
2017-12-312018-03-05$1.19 million-$0.80-$0.77-3.67%
2017-09-302017-11-07$305000-$0.68-$0.8216.63%
2017-06-302017-08-10$305000-$0.70-$0.8214.83%
2017-03-312017-05-08$305000-$0.71-$0.710.56%
2016-12-312017-03-02$305000-$0.59-$0.7419.79%
2016-09-302016-11-10$305000-$0.84-$0.82-2.78%
2016-06-302016-08-09$305000-$0.47-$0.5412.18%
2016-03-312016-05-16$305000-$0.73-$0.48-52.22%

Syndax Pharmaceuticals, Inc (SNDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Syndax Pharmaceuticals, Inc (SNDX) Chart:

Syndax Pharmaceuticals, Inc (SNDX) News:

Below you will find a list of latest news for Syndax Pharmaceuticals, Inc (SNDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syndax Pharmaceuticals, Inc (SNDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-04-192.518.6CALL0 00TRUE00
2024-04-19516CALL0 00TRUE00
2024-04-197.56.4CALL0 50TRUE00
2024-04-191012.03CALL0 201375.81TRUE00
2024-04-1912.57.8CALL0 11013.46TRUE00
2024-04-19158.2CALL0 58719.1TRUE00
2024-04-1917.55.2CALL0 62479.79TRUE00
2024-04-19202.21CALL0 153237.74TRUE00
2024-04-1922.50.1CALL83 1512137.28FALSE0.10
2024-04-19250.05CALL20 1567213.52FALSE0.050
2024-04-19300.2CALL0 31290FALSE00
2024-04-19350.05CALL0 15200FALSE00
2024-04-192.50PUT0 00FALSE00
2024-04-1950PUT0 00FALSE00
2024-04-197.50.2PUT0 10FALSE00
2024-04-19100.51PUT0 130FALSE00
2024-04-1912.50.3PUT0 10FALSE00
2024-04-19150.06PUT0 360FALSE00
2024-04-1917.50.11PUT0 8450FALSE00
2024-04-19200.1PUT1 183683.28FALSE0.10
2024-04-1922.52.05PUT2 1100202.96TRUE0.460.29
2024-04-19252.7PUT0 177462.25TRUE00
2024-04-193013.7PUT0 1529.98TRUE00
2024-04-19350PUT0 0771.85TRUE00
2024-05-1712.50CALL0 0193.62TRUE00
2024-05-17150CALL0 0144.7TRUE00
2024-05-1717.50CALL0 094.87TRUE00
2024-05-17203.2CALL0 283.68TRUE00
2024-05-1722.50.8CALL24 4761.35FALSE0.80
2024-05-17251CALL0 1469.76FALSE00
2024-05-17300.2CALL0 686.11FALSE00
2024-05-17350.15CALL0 80FALSE00
2024-05-1712.50PUT0 00FALSE00
2024-05-17150PUT0 00FALSE00
2024-05-1717.50.25PUT0 4074.14FALSE00
2024-05-17201.05PUT10 27162.25FALSE0.150.17
2024-05-1722.52.5PUT4 4262.49TRUE2.50
2024-05-17253.16PUT0 4055.61TRUE00
2024-05-17300PUT0 0100.54TRUE00
2024-05-17350PUT0 0206.68TRUE00
2024-07-192.50CALL0 0290.22TRUE00
2024-07-1950CALL0 0187.32TRUE00
2024-07-197.50CALL0 0156.31TRUE00
2024-07-191011.86CALL0 3122.78TRUE00
2024-07-1912.511.5CALL0 198.75TRUE00
2024-07-19156.38CALL2 664.69TRUE-0.02-0
2024-07-1917.56.4CALL0 1165.71TRUE00
2024-07-19202.8CALL76 3355.9TRUE-0.5-0.15
2024-07-1922.53.5CALL0 7861.63FALSE00
2024-07-19251.1CALL20 10157.61FALSE1.10
2024-07-19301.4CALL0 1758.63FALSE00
2024-07-19350.63CALL0 165.31FALSE00
2024-07-192.50PUT0 00FALSE00
2024-07-1950PUT0 00FALSE00
2024-07-197.50PUT0 00FALSE00
2024-07-19100PUT0 00FALSE00
2024-07-1912.50.3PUT0 2184.61FALSE00
2024-07-19150.7PUT0 1960.14FALSE00
2024-07-1917.50.9PUT0 5559.23FALSE00
2024-07-19201.7PUT0 3758.28FALSE00
2024-07-1922.52.5PUT0 155.17TRUE00
2024-07-19254.3PUT0 4159.31TRUE00
2024-07-19308.47PUT0 34260.12TRUE00
2024-07-19350PUT0 0103.4TRUE00
2024-10-1812.50CALL0 095.61TRUE00
2024-10-18150CALL0 066.35TRUE00
2024-10-1817.50CALL0 071.46TRUE00
2024-10-18200CALL0 069.04TRUE00
2024-10-1822.54.52CALL0 11471.43FALSE00
2024-10-18253.28CALL0 22068.96FALSE00
2024-10-18302CALL50 34268.27FALSE20
2024-10-18350CALL0 074.97FALSE00
2024-10-1812.50PUT0 073.51FALSE00
2024-10-18151.04PUT0 1373.08FALSE00
2024-10-1817.51.9PUT0 969.96FALSE00
2024-10-18200PUT0 069.5FALSE00
2024-10-1822.50PUT0 068.23TRUE00
2024-10-18250PUT0 067.57TRUE00
2024-10-18300PUT0 067.72TRUE00
2024-10-18350PUT0 065.6TRUE00
2025-01-172.50CALL0 0203.19TRUE00
2025-01-1750CALL0 0151.72TRUE00
2025-01-177.50CALL0 0111.7TRUE00
2025-01-17100CALL0 095.93TRUE00
2025-01-1712.57.5CALL0 297.1TRUE00
2025-01-171510CALL0 8100.37TRUE00
2025-01-1717.58.05CALL2 993.36TRUE8.050
2025-01-17207.23CALL0 3088.38TRUE00
2025-01-1722.56.85CALL0 7986.36FALSE00
2025-01-17255.1CALL2 53787.64FALSE5.10
2025-01-17305CALL0 16484.78FALSE00
2025-01-17352.76CALL0 1287.06FALSE00
2025-01-172.50PUT0 00FALSE00
2025-01-1750PUT0 00FALSE00
2025-01-177.50PUT0 00FALSE00
2025-01-17100.72PUT0 991.55FALSE00
2025-01-1712.50PUT0 088.66FALSE00
2025-01-17154.8PUT0 291.23FALSE00
2025-01-1717.52.35PUT0 5487.71FALSE00
2025-01-17204.7PUT0 7185.98FALSE00
2025-01-1722.56.4PUT0 10282.88TRUE00
2025-01-17256.9PUT0 282.96TRUE00
2025-01-173010.5PUT0 34983.9TRUE00
2025-01-17350PUT0 085.7TRUE00
2026-01-162.520.5CALL0 180.13TRUE00
2026-01-1650CALL0 096.61TRUE00
2026-01-167.50CALL0 087.21TRUE00
2026-01-16100CALL0 078.09TRUE00
2026-01-1612.50CALL0 071.28TRUE00
2026-01-16150CALL0 071.95TRUE00
2026-01-1617.50CALL0 073.53TRUE00
2026-01-162010.8CALL0 275.01TRUE00
2026-01-1622.510.3CALL0 372.04FALSE00
2026-01-16258.63CALL0 472.89FALSE00
2026-01-16306.6CALL0 2271.37FALSE00
2026-01-16350CALL0 070.48FALSE00
2026-01-162.50PUT0 00FALSE00
2026-01-1650PUT0 00FALSE00
2026-01-167.50PUT0 0111.76FALSE00
2026-01-16100PUT0 068.53FALSE00
2026-01-1612.50PUT0 078.22FALSE00
2026-01-16150PUT0 071.24FALSE00
2026-01-1617.50PUT0 070.62FALSE00
2026-01-16200PUT0 072.03FALSE00
2026-01-1622.50PUT0 070.69TRUE00
2026-01-16250PUT0 073.27TRUE00
2026-01-16300PUT0 070.37TRUE00
2026-01-16350PUT0 072.45TRUE00

Latest SNDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST3$15.6
Jun 13, 2022 7:59 PM EST4$15.6
Jun 13, 2022 7:59 PM EST1$15.6
Jun 13, 2022 7:59 PM EST100$15.61
Jun 13, 2022 7:59 PM EST45$15.61

Syndax Pharmaceuticals, Inc (SNDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2019-09-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395937/000000000019013216/0000000000-19-013216-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000021545719006549/0000215457-19-006549-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720006818/0000834237-20-006818-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720010194/0000834237-20-010194-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221919000254/0000902219-19-000254-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221920000308/0000902219-20-000308-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266419001816/0000902664-19-001816-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266420000971/0000902664-20-000971-index.htm
2020-11-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000091957420006675/0000919574-20-006675-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518001976/0000921895-18-001976-index.htm
2018-11-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518003173/0000921895-18-003173-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189519000467/0000921895-19-000467-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189520000574/0000921895-20-000574-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359419000160/0001013594-19-000160-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359420000127/0001013594-20-000127-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/0001140361-18-018005-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018007/0001140361-18-018007-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312518197997/0001193125-18-197997-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519034379/0001193125-19-034379-index.htm
2019-03-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519088951/0001193125-19-088951-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312519092679/0001193125-19-092679-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519092701/0001193125-19-092701-index.htm
2019-08-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1395937/000119312519235283/0001193125-19-235283-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395937/000119312519239953/0001193125-19-239953-index.htm
2019-09-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519242045/0001193125-19-242045-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519265254/0001193125-19-265254-index.htm
2020-02-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312520022917/0001193125-20-022917-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312520023646/0001193125-20-023646-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520037637/0001193125-20-037637-index.htm
2020-05-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520139263/0001193125-20-139263-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002680/0001562180-18-002680-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002681/0001562180-18-002681-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002682/0001562180-18-002682-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002683/0001562180-18-002683-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002684/0001562180-18-002684-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002685/0001562180-18-002685-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004047/0001562180-18-004047-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004048/0001562180-18-004048-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/0001562180-18-004049-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004050/0001562180-18-004050-index.htm
2018-11-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000852/0001562180-19-000852-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/0001562180-19-000853-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000854/0001562180-19-000854-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000855/0001562180-19-000855-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/0001562180-19-000856-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/0001562180-19-002023-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003487/0001562180-19-003487-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003488/0001562180-19-003488-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003489/0001562180-19-003489-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003490/0001562180-19-003490-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/0001562180-19-003491-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003492/0001562180-19-003492-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003880/0001562180-19-003880-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001228/0001562180-20-001228-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/0001562180-20-001229-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001230/0001562180-20-001230-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001231/0001562180-20-001231-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001232/0001562180-20-001232-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001233/0001562180-20-001233-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/0001562180-20-001234-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001235/0001562180-20-001235-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/0001562180-20-001236-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001237/0001562180-20-001237-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-07-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005102/0001562180-20-005102-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018004520/0001564590-18-004520-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/0001564590-18-004911-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018011784/0001564590-18-011784-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/0001564590-18-012378-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018014349/0001564590-18-014349-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018019907/0001564590-18-019907-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018020483/0001564590-18-020483-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/0001564590-18-020504-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018023593/0001564590-18-023593-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018026817/0001564590-18-026817-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018026892/0001564590-18-026892-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019002676/0001564590-19-002676-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/0001564590-19-006772-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019006777/0001564590-19-006777-index.htm
2019-03-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019008313/0001564590-19-008313-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019014263/0001564590-19-014263-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019015972/0001564590-19-015972-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/0001564590-19-017318-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019022241/0001564590-19-022241-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019024625/0001564590-19-024625-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030050/0001564590-19-030050-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019030067/0001564590-19-030067-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/0001564590-19-030084-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019036518/0001564590-19-036518-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019041712/0001564590-19-041712-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/0001564590-19-041719-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019045581/0001564590-19-045581-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020004037/0001564590-20-004037-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020005551/0001564590-20-005551-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020008426/0001564590-20-008426-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/0001564590-20-009016-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019694/0001564590-20-019694-index.htm
2020-04-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020019928/0001564590-20-019928-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019941/0001564590-20-019941-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020020574/0001564590-20-020574-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020020633/0001564590-20-020633-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020022849/0001564590-20-022849-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020022971/0001564590-20-022971-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020031882/0001564590-20-031882-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037719/0001564590-20-037719-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/0001564590-20-037767-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/0001564590-20-037777-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020049638/0001564590-20-049638-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020051287/0001564590-20-051287-index.htm
2019-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395937/999999999519002056/9999999995-19-002056-index.htm
2018-11-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999716026189/9999999997-16-026189-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718004150/9999999997-18-004150-index.htm
2018-06-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718006372/9999999997-18-006372-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718007508/9999999997-18-007508-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718009113/9999999997-18-009113-index.htm
2019-03-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999719002097/9999999997-19-002097-index.htm

Syndax Pharmaceuticals, Inc (SNDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syndax Pharmaceuticals, Inc (SNDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 645%
Institutional Ownership: 7888%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-03Peter OrdentlichChief Scientific OfficerSell7,500.0015.00112,500.000.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2020-07-06Michael L. MeyersSVP, Chief Medical OfficerBuy3,500.0010,730.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-11-04Michael A MetzgerPresident and COOBuy100,000.007.20720,000.00117,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-09Briggs MorrisonChief Executive OfficerBuy13,200.007.5699,726.0013,200.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2020-02-12Michael A MetzgerPresident and COOBuy15,000.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-11-04Michael A MetzgerPresident and COOSell100,000.0020.312,031,410.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-13Briggs MorrisonChief Executive OfficerBuy7,200.007.2952,516.8020,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2018-10-30Michael L. MeyersSVP, Chief Medical OfficerBuy200.004.79958.002,398.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-10-10Briggs MorrisonChief Executive OfficerBuy11,000.005.4059,400.0031,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-04Briggs MorrisonChief Executive OfficerBuy12,500.008.00100,000.0043,900.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy1,000.004.934,930.007,118.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy104.004.87506.487,222.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2018-04-03Peter OrdentlichChief Scientific OfficerBuy7,500.003.0823,100.007,500.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm